Pegylated arginine deiminase: a novel anticancer enzyme agent
In the OASIS-1 study, 13% of participants (people with obesity without diabetes) receiving oral semaglutide 50 mg experienced altered skin sensation events compared to 1% with placebo - these events were generally mild to moderate in severity, occurred during dose escalation to the higher doses and resolved without requiring permanent treatment discontinuation [21]
Effect of dietary pyrroloquinoline quinone disodium salt on cognitive function in healthy volunteers: A randomized, double-blind, placebo-controlled, parallel-group study
Szukalska M, Szyfter K, Florek E, Rodrigo JP, Rinaldo A, Mkitie AA, et al
Patients on immunosuppressive therapy should have a provider review potential interactions before initiating any peptide protocol